{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:26:31Z","timestamp":1788978391490,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T00:00:00Z","timestamp":1403308800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00277-014-2126-9","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T10:05:31Z","timestamp":1403258731000},"page":"1825-1838","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group"],"prefix":"10.1007","volume":"93","author":[{"given":"Lisa","family":"Pleyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Burgstaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Girschikofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Linkesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Stauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfeilstocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schreder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Tinchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer","family":"Sliwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alois","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Krippl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Voskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Schlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Machherndl-Spandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Theiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Eckm\u00fcllner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,21]]},"reference":[{"issue":"1","key":"2126_CR1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/beha.2000.0116","volume":"14","author":"B Lowenberg","year":"2001","unstructured":"Lowenberg B (2001) Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 14(1):65\u201375","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"2126_CR2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3322\/canjclin.52.6.363","volume":"52","author":"RM Stone","year":"2002","unstructured":"Stone RM (2002) The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 52(6):363\u2013371","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2126_CR3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223\u2013232","journal-title":"Lancet Oncol"},{"issue":"4","key":"2126_CR4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","volume":"28","author":"P Fenaux","year":"2010","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28(4):562\u2013569","journal-title":"J Clin Oncol"},{"issue":"1","key":"2126_CR5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2011.606382","volume":"53","author":"HK Al Ali","year":"2012","unstructured":"Al Ali HK, Jaekel N, Junghanss C, Maschmeyer G, Krahl R, Cross M et al (2012) Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I\/II study. Leuk Lymphoma 53(1):110\u2013117","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2126_CR6","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3324\/haematol.2012.065151","volume":"97","author":"M Gavillet","year":"2012","unstructured":"Gavillet M, Noetzli J, Blum S, Duchosal MA, Spertini O, Lambert JF (2012) Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine. Haematologica 97(12):1929\u20131931","journal-title":"Haematologica"},{"issue":"4","key":"2126_CR7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.26354","volume":"118","author":"L Maurillo","year":"2012","unstructured":"Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E et al (2012) Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian compassionate program. Cancer 118(4):1014\u20131022","journal-title":"Cancer"},{"issue":"1","key":"2126_CR8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-8722-6-32","volume":"6","author":"L Pleyer","year":"2013","unstructured":"Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M et al (2013) Azacitidine in patients with WHO-defined AML\u2014results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol 6(1):32","journal-title":"J Hematol Oncol"},{"issue":"24","key":"2126_CR9","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","volume":"24","author":"LR Silverman","year":"2006","unstructured":"Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24(24):3895\u20133903","journal-title":"J Clin Oncol"},{"issue":"8","key":"2126_CR10","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/cncr.22204","volume":"107","author":"N Sudan","year":"2006","unstructured":"Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB et al (2006) Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 107(8):1839\u20131843","journal-title":"Cancer"},{"issue":"19","key":"2126_CR11","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","volume":"116","author":"S Thepot","year":"2010","unstructured":"Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y et al (2010) Treatment of progression of Philadelphia negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies. Blood 116(19):3735\u20133742","journal-title":"Blood"},{"issue":"4","key":"2126_CR12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ajh.23654","volume":"89","author":"S Thepot","year":"2014","unstructured":"Thepot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B et al (2014) Azacitidine in untreated acute myeloid leukemia. A report on 149 patients. Am J Hematol 89(4):410\u2013416","journal-title":"Am J Hematol"},{"issue":"5","key":"2126_CR13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.2011.08893.x","volume":"155","author":"LH Helm van der","year":"2011","unstructured":"van der Helm LH, Alhan C, Wijermans PW, van Marwijk KM, Schaafsma R, Biemond BJ et al (2011) Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 155(5):599\u2013606","journal-title":"Br J Haematol"},{"issue":"8","key":"2126_CR14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2013.03.022","volume":"37","author":"LH Helm van der","year":"2013","unstructured":"van der Helm LH, Veeger NJ, Kooy M, Beeker A, de Weerdt O, de Groot M et al (2013) Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30\u00a0% bone marrow blasts. Leuk Res 37(8):877\u2013882","journal-title":"Leuk Res"},{"issue":"4","key":"2126_CR15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.leukres.2014.01.006","volume":"38","author":"L Pleyer","year":"2014","unstructured":"Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R et al (2014) Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res 38(4):475\u2013483","journal-title":"Leuk Res"},{"issue":"24","key":"2126_CR16","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642\u20134649","journal-title":"J Clin Oncol"},{"issue":"2","key":"2126_CR17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108(2):419\u2013425","journal-title":"Blood"},{"issue":"7","key":"2126_CR18","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children\u2019s Leukaemia Working Parties. Blood 92(7):2322\u20132333","journal-title":"Blood"},{"issue":"4","key":"2126_CR19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2008.04.013","volume":"35","author":"H Dombret","year":"2008","unstructured":"Dombret H, Raffoux E, Gardin C (2008) Acute myeloid leukemia in the elderly. Semin Oncol 35(4):430\u2013438","journal-title":"Semin Oncol"},{"issue":"6","key":"2126_CR20","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079\u20132088","journal-title":"Blood"},{"issue":"8","key":"2126_CR21","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919","journal-title":"Blood"},{"issue":"2","key":"2126_CR22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2011-07-367508","volume":"119","author":"S Kayser","year":"2012","unstructured":"Kayser S, Zucknick M, Dohner K, Krauter J, Kohne CH, Horst HA et al (2012) Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 119(2):551\u2013558","journal-title":"Blood"},{"issue":"29","key":"2126_CR23","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","volume":"26","author":"DA Breems","year":"2008","unstructured":"Breems DA, Van Putten WL, De Greef GE, Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH et al (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26(29):4791\u20134797","journal-title":"J Clin Oncol"},{"issue":"4","key":"2126_CR24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3324\/haematol.2011.043208","volume":"96","author":"DA Breems","year":"2011","unstructured":"Breems DA, Lowenberg B (2011) Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica 96(4):491\u2013493","journal-title":"Haematologica"},{"issue":"22","key":"2126_CR25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood.V114.22.843.843","volume":"114","author":"S Thepot","year":"2009","unstructured":"Thepot S (2009) IRSVRCQBDJCTeal. Azacytidine (AZA) as first line therapy in AML: results of the French ATU Program. Blood 114(22):843","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2126-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2126-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2126-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T05:48:32Z","timestamp":1597988912000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2126-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,21]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["2126"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2126-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,21]]}}}